

**Sphere Medical Holding Ltd**  
(‘Sphere Medical’ or ‘Sphere’)

**Fund raising of £6.2 Million**

**Sphere Medical Holding Limited**, the Cambridge (UK) based medical microtech company, is pleased to announce that it has raised £6.2 million through the issue of shares. It is pleased to welcome new shareholders including Oxford Capital Partners, Fritas A/S (wholly owned by Ove Hoegh and family) and funds managed on a discretionary basis by Schroder Investment Management Limited. The issue has also received strong support from existing shareholders including further investment by Artemis Investment Management Limited, Herald Ventures, Hotbed Limited and The Generics Group. Hotbed Limited and Eden Financial Limited, the independent stock-broking and asset management group, assisted in the fund raising.

The proceeds will strengthen the balance sheet to support ongoing commercial discussions and will continue to fund the development and production scale-up of Sphere’s microchip-based medical products.

To date Sphere, whose technology was borne out of Siemens, has raised more than £11 million via two funding rounds. Sphere’s micro-analyser technology is applicable over a wide variety of applications and can simultaneously measure numerous important clinical parameters such as glucose levels and blood gas concentrations in real time allowing patients to be kept in the therapeutic window which results in more efficient treatment and quicker recovery times.

**Dr. Stuart Hendry, Sphere Medical’s Chief Executive Officer, said:**

“I am especially pleased to welcome such high quality new investors as well as to receive support from our existing shareholders. Over the last year Sphere has achieved considerable progress and we have reached the position where expert observers believe that products such as Sphere’s are an inevitability of the future of intensive care. Sphere believes that its products will contribute significantly to the improvement of patient care, outcomes and cost in critical care units around the world.”

**For more information please contact:**

**Sphere Medical Holding Limited**  
Dr. Stuart Hendry, Chief Executive Officer  
+44 (0)1223 875222  
[www.spheremedical.com](http://www.spheremedical.com)

**Buchanan Communications**  
Tim Anderson, Mary-Jane Johnson  
+44 (0) 20 7466 5000

Artemis Investment Management Limited  
Lindsay Whitelaw  
+44 (0)800 092 2051  
[www.artemisfunds.com](http://www.artemisfunds.com)

Eden Financial Limited  
Martin Hall  
+44 (0)20 7509 7483  
[www.edenfinancial.com](http://www.edenfinancial.com)

For issue on RNS Reach at 07:00 on Monday 22<sup>nd</sup> May 2006

The Generics Group AG  
Martin Frost  
+44 (0) 1223 875200  
[www.genericsgroup.com](http://www.genericsgroup.com)

Andy Tan  
Hansard Communications  
+(44) 20 7245 1100

Herald Ventures  
Tom Hayward  
+44 (0)20 7553 6300  
[www.heraldventures.com](http://www.heraldventures.com)

Hotbed Limited  
Roger Swift  
+44 (0)1908 523440  
[www.hotbed.uk.com](http://www.hotbed.uk.com)

Oxford Capital Partners  
David Mott  
+44 (0)1865 860760  
[www.oxcp.com](http://www.oxcp.com)

Schroder Investment Management Limited  
[contact name]  
+44 (0)20 7658 6000  
[www.schroders.com](http://www.schroders.com)

### **About Sphere Medical Holding Limited**

**Sphere Medical**, the Cambridge, UK based medical microtech company ([www.spheremedical.com](http://www.spheremedical.com)), is developing micro-analysers which can measure simultaneously numerous important clinical parameters in real time. The disposable micro-analyser platform, which is based on technology originally acquired from Siemens, can be applied to numerous clinical needs at very cost effective price points. The initial commercial application of the micro-analyser will be the real time measurement of glucose levels, blood gas concentrations and electrolyte levels in a number of clinical application areas. Sphere Medical is also developing novel receptor technology, enabling the measurement of drugs and disease markers, as part of its strategy to increase the commercial applications of its patented micro-analyser system.

Real-time monitoring of drugs, physiological parameters, and disease markers has the potential to facilitate titration and, ultimately, closed loop control of a broad variety of therapies. **Sphere Medical** is working with a number of the world's leading clinicians in the USA and Europe to realise this goal.

Commercialised products will be marketed globally through multi-national marketing and distribution partners. The costs associated with the conditions and complications addressed by its products are in the order tens of billions of US\$ in the Intensive Care Unit alone. With limited alternative solutions currently available, **Sphere Medical** estimates that the total market addressed by its initial products is around US\$2.2 billion a year.

**[www.spheremedical.com](http://www.spheremedical.com)**